固本化积汤联合化疗治疗晚期非小细胞肺癌的临床观察

Clinical study of integrated Gubenhuaji decoction and chemotherapy in treating non-small cell lung cancer

目的观察固本化积汤联合化疗治疗晚期非小细胞肺癌的近期疗效。方法将194例晚期非小细胞肺癌患者随机分为2组。治疗组102例采用固本化积汤(每日1剂,1个月为1个疗程,共治疗3个疗程)配合化疗(NP或VP方案,3周为1个疗程,共治疗3个疗程)治疗。对照组92例单纯予化疗,方法同治疗组。观察2组瘤体大小变化、生活质量、体质量、主要症状改善情况及不良反应情况。结果治疗组瘤体变化有效率28.4%,对照组13.0%,2组比较差异有统计学意义(P<0.01);治疗组治疗后卡氏评分与本组治疗前及对照组治疗后比较差异均有统计学意义(P<0.01);对照组治疗后体质量与本组治疗前及治疗组治疗后比较差异均有统计学意义(P<0.01);治疗组预后情况、症状改善情况均优于对照组(P<0.05,P<0.01)。治疗组不良反应情况少于对照组(P<0.05,P<0.01)。结论固本化积汤联合化疗治疗晚期非小细胞肺癌近期疗效优于单纯化疗,可作为晚期非小细胞肺癌的有效治疗方案。

Objective To observe the short term therapeutic efficacy of integrated Gubenhuaji Decoction and chemotherapy （IGDC） in treating non- small cell lung cancer（NSCLC） in Ⅲ and Ⅳ phase. Methods 194 patients with non - small cell cancer（NSCLC） in Ⅲ and Ⅳ phase were randomly divided into the IGDC group （ n = 102） and the Western medicine （WM） group （ n = 92）. Patients in the IGDC group were treated by integrated Gubenhuaji decoction and chemo- therapy. Patients in WM group were treated by chemotherapy. The excluded or dropping off cases were 10 in IGDC and 15 in WM. Clinical trials were conducted in 3 hospitals and 3 months of treatment was taken as one therapeutic course. The main observation indexes were tumor size, quality of life, Karnofsky scores, body weight, adverse reaction, etc. Results The total effective rate of tumor remission in the IGDC group and WM group were 28.4% and 13.0%, respectively. There was statistical significance between two groups （ P 〈 0.01 ）. Kamoiksy score significantly raised in the IGDC group after treatment in comparison with that before treatment （ P 〈 0.01 ）. The kamofsky score in IGDC group was higher than that in WM after treatment （ P 〈 0.01 ）. The patient＇ s body weights in the 2 groups were all reduced. The reduction in the IGDC group was lower than that in WM group （ P 〈 0.01 ）. The effect in the IGDC group was better than that in WM group in aspects of improving such tumor related symptoms as cough, short breath, anorexia, fatigue, etc （P 〈0.01, P 〈0.05）. Adverse reaction in the IGDC group was lesser than that in the WM group （ P 〈 0.05, P 〈 0,01）. Conclusion IGDC therapy showed better short - term efficacy in treating patients with NSCLC than WM alone. It can be adopted as an effective therapeutic program.